

Prequel 1: October 2, 2003

- *Public Meeting on Clinical Data Interchange Standard Consortium (CDISC) Version 3 Submission Data Standards and Electronic Case Report Tabulations*
- “Web Submission Data Manager (WebSDM) DEMONSTRATION”
- eDR vs. WebSDM

Prequel 2: Standards Development - Unprecedented Collaboration



An FDA Statistical Reviewer Perspective:
**Analysis Data Submissions &
Wrap-up of FDA perspectives**

CAPT Steve Wilson, DrPH

Deputy Director

Division of Biometrics II,
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

*Update on the Study Data Tabulation Model
for FDA Submissions Public Meeting*

Rockville, MD

Tuesday, February 1, 2005

Disclaimer

Views expressed in this presentation are those of the speaker and not, necessarily, of the Food and Drug Administration.

Acknowledgements

- Rafia Bhore
- Andrea James
- Wayne Kubick
- Becky Kush
- Randy Levin
- Cynthia Liu
- Ed Nevius
- Armando Oliva
- Tom Papoian
- Norm Stockbridge
- CDISC SDM and ADaM Teams

Outline

- Analysis Data Submissions
 - Statistical Review
 - Current Guidance
 - First Experience
 - ADaM – General Considerations
- Wrap-up of FDA Perspectives
 - Standards development
 - SDTM Review
 - Challenges

Why Standards?

Improve time to market for safe and effective treatments (increased patient safety and reduced costs)

- Improve efficiency for clinical research
 - Facilitates design and conduct of clinical trials
 - Facilitates communication between researchers and study sponsor (e.g., between CRO and drug company)
- Improves efficiency of evaluation of safety and efficacy of investigational treatments
 - Facilitates communication between regulatory authority and applicant
 - Facilitates development of efficient review environment (e.g., training, analysis tools)

Efficient Review Environment

- Standards provide:
 - Common structure and terminology
 - Single data source for review (less redundant data)
- Standards allow:
 - Use of common tools and techniques
 - Common training
 - Single validation of data


Statistical Review of Clinical Trials Data

- Efficacy **and safety**
- Confirmatory/Exploratory- focus on evaluating sponsor's results
- Check appropriateness of statistical models and conclusions - programs & analysis datasets
- Assess quality/completeness of data
- Evaluate the impact of sponsor's analytical decisions - derived variables, missing/messy data ("quirks" - R. Helms) - sensitivity analyses
- Answer new, review-related statistical questions
- Communication with sponsors
- Archive results

Statistical Review Environment

- No programmers
- Multiple projects
- Increasingly electronic world
- Understaffed
- Good review practice not well described
- Without standards every review is an adventure
- Communication with sponsor

Submission Files



Today's Mantra

SDTM and Analysis Datasets

BOTH

ARE NEEDED FOR REVIEW!

(for now)

Current Guidance

- Guidance, 1999
 - *Providing Regulatory Submissions in Electronic Format – NDAs*
- *Data Specifications, 2004*
 - “Study Data Tabulation Model (SDTM) developed by the Submission Data Standard working group of the Clinical Data Interchange Standard Consortium (CDISC)”

Electronic Submission NDA, 1999

K. Item 11: Case Report Tabulations (CRTs)

“...Prior to the submission, you should **discuss with the review division** the datasets to be provided and the data elements that should be included in each dataset...

The data organization varies from indication to indication. Prior to the submission, **you should discuss with the review division the datasets that should be provided**, the data elements that should be included in each dataset, and the organization of the data within the file.”

Study Data Specifications

- Individual subject data listings
 - Data tabulations
 - +Data tabulations datasets
 - +Data definitions
 - Data listing
 - +Data listing datasets
 - +Data definitions
 - Analysis datasets
 - +Analysis datasets
 - +Analysis programs
 - +Data definitions

Data Specifications: Analysis Datasets

Definition

- Analysis datasets are datasets created to support specific analyses.
- Programs are scripts used with selected software to produce reported analyses based on these datasets.

Data Specifications: Analysis Datasets

Specifications

- Each dataset is provided as a SAS Transport (XPORT) file.
- Programs should be provided as both ASCII text and PDF files and should include sufficient documentation to allow a reviewer to understand the submitted programs.
- It is not necessary to provide analysis datasets and programs that will enable the reviewer to directly reproduce reported results using agency hardware and software.
- Currently, there are no other additional specifications for creating analysis datasets.

CDISC-it! A First Experience: Some Lessons Learned

- Submission with SDTM Datasets
 - Statistical Reviewer
 - Analysis Datasets
 - Training

CDISC-it! A First Experience: SDTM Submission: Statistical Review

- Shortly after submission -- training for medical reviewers and statisticians on WebSDM provided by Lincoln
- Statistician not able to start review until recently
- Good SAS skills
- Now looking at statistical review using both SDTM files and analysis files
- Use experience in developing additional feedback

CDISC-it! A First Experience:

Some Lessons Learned

- Familiarity with standard data
- FDA Tools needed to work with SDTM datasets
 - SDTM with WebSDM is big advantage over eDR data
- Need more experience – More resources devoted to on-time training, hand-holding – we need and want to work with you!
- Give SDTM submissions “special attention”
- Does not eliminate need for communication between sponsor and reviewers during review
- Need more real world test of SDTM and “real” trial data

SDTM & Analysis Datasets

- Currently, SDTM describes observations from a clinical trial
- SDTM (with appropriate tools) is particularly useful in medical officer evaluation of safety
- It is well recognized that datasets that are used in the analysis have been restructured and contain additional information (derived variables, flags, comments, etc.)
- To **facilitate communication** between statistical reviewers and sponsors, there is a need to **standardize the documentation and content** of these datasets
- The CDISC/ADaM Team has a guidance describing the documentation of analysis files.

Progress: New Guidance from CDISC/ADaM Team



Statistical Analysis Dataset Model: General Considerations Version 1.0

**Prepared by the
CDISC Analysis Dataset Modeling Team
(ADaM)**

- <http://www.cdisc.org>

ADaM Guidance: Guiding Principle

- “The overall principle in designing Statistical Analysis Datasets and related metadata is that there must be clear and **unambiguous communication** of the content, source and quality of the datasets submitted in support of the statistical analysis performed by the sponsor.”
- Would **support the machine-readable description for the JANUS** data repository

ADaM Guidance

- **Build on SDTM:** “Statistical analysis Dataset Metadata conforms to the CDISC Submission Metadata Model”
- Include proposed descriptions of:
 - Analysis-level metadata
 - Dataset-level metadata
 - Variable-level metadata
 - Value-level metadata

ADaM Guidance: Analysis-level Metadata

- **ANALYSIS NAME** - A unique identifier for this analysis. May include a table number or other sponsor-specific reference.
- **DOCUMENTATION** - A text description documenting the analysis performed.
- **REASON** - The reason for performing this analysis. Examples may include Pre-specified, Data-driven, Exploratory, and Regulatory Request.
- **DATASET** - the name of the analysis dataset used should be linked to the analysis dataset used for this analysis. In most cases, this will be a single dataset. If multiple datasets are used, they should all be listed here.
- **PROGRAM** - Analysis programs using the DATASET above as input can be described or included here.

ADaM Guidance: Dataset-level Metadata

Example Statistical Analysis Dataset Metadata					
Dataset	Description of Dataset	Structure	Purpose	Keys	Location
sbc	Subject/Baseline Characteristics	One record per subject	Analysis	USUBJID	<u>crt/datasets/111/sbc.xpt</u>
vsstat	Vital Signs Stat Analysis	One record per subject per visit	Analysis	USUBJID VISITNUM	<u>crt/datasets/111/vsstat.xpt</u>

ADaM Guidance: Variable-level Metadata

- Identifier and Qualifier Variables
- Statistical Analysis Variable Roles
- Analysis Population Indicator Variables
- Imputation Indicator Variables
- Statistical Analysis Date Variables
- Statistical Analysis Study Day Variables
- Visit Timing Variables
- Numeric Code Variables
- Statistical Analysis Treatment Variables

ADaM Guidance: Value-level Metadata

- For variables containing more than one type of measure
- Allow transformation of data back and forth between “vertical” and “horizontal” dataset structures.
- Part of proposed CDISC DEFINE.XML standard

Regulation



Guidance



Adapted from S. Woollen

Wrap-Up of FDA Perspectives

- Standards Development – Big Picture – Healthcare/Clinical Trials
 - Patient Record / HL7
 - Protocol
 - Operational Data Model
 - eSDI
- FDA Data Standards Council – Coordinating activities of all Centers
 - CBER Pilot – Gene Therapy, Vaccines
 - CVM, CFSAN - evaluating

Wrap-Up of FDA Perspectives

- It's ALL SDTM
 - Medical review – SDTM/SDS
 - Statistical review – SDTM/ADaM
 - PharmTox review – SDTM/SEND
- Review not dependent on specific tool(s) – “It's all data”
- Future development – JANUS
- Requirements – Rule-making

Challenges

- Still need to do the work -- get reviews done
- Work with minimal resources
- Good review practice
- Moving target – efficacy **and safety**
- Science – therapeutic areas
- Communication: External and Internal
- Buy-in (CDISC-it!)
- Lessons learned – evaluation
- Training – experience (no missed opportunities)
- Next Steps vs. “Vision” Thing
- Adopting Change
- Effective/ Efficient Collaboration
- Guidance/ Communication

That Fast Efficient, High Quality Review Machine



CDISC-it!

Thank You